

## Expences relating to reagents production (Proceeds Allocated: Approx. 4.9 billion yen)

### Output

- Expansion of manufacturing facilities for fermentation and purification, including installments of tanks and equipment

### Outcome

- Production capacity: Approx. 1.5-fold increase compared to FY 3/20
- Start of operation: Started from April 2024

### Impact

- Maintained global medical systems
- Contribution to clinical biochemistry
- Future expansion of overseas development centering on emerging countries.

### Current status

Global share: Approx. 25% (our estimate) No.2

Overseas sales ratio: Approx. 70%



Enzymes for biochemical diagnostic reagents

Blood glucose (Diabetes), Cholesterol (Arteriosclerosis), Creatinine (Renal function), GOT / GPT (Liver function) etc.



Appearance of new equipment for culture and purification at Tsuruga Biochemicals Plant